234 related articles for article (PubMed ID: 29066370)
1. Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems.
Lu M; Li J; Haller IV; Romanelli RJ; VanWormer JJ; Rodriguez CV; Raebel MA; Boscarino JA; Schmidt MA; Daida YG; Sahota A; Vincent J; Bowlus CL; Lindor K; Rupp LB; Gordon SC;
Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1333-1341.e6. PubMed ID: 29066370
[TBL] [Abstract][Full Text] [Related]
2. Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment.
Lu M; Zhou Y; Haller IV; Romanelli RJ; VanWormer JJ; Rodriguez CV; Anderson H; Boscarino JA; Schmidt MA; Daida YG; Sahota A; Vincent J; Bowlus CL; Lindor K; Zhang T; Trudeau S; Li J; Rupp LB; Gordon SC;
Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1342-1350.e1. PubMed ID: 29277621
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis.
Gordon SC; Wu KH; Lindor K; Bowlus CL; Rodriguez CV; Anderson H; Boscarino JA; Trudeau S; Rupp LB; Haller IV; Romanelli RJ; VanWormer JJ; Schmidt MA; Daida YG; Sahota A; Vincent J; Zhang T; Li J; Lu M;
Am J Gastroenterol; 2020 Feb; 115(2):262-270. PubMed ID: 31985529
[TBL] [Abstract][Full Text] [Related]
4. Epidemiological and clinical features of primary biliary cholangitis in two Croatian regions: a retrospective study.
Madir A; Božin T; Mikolašević I; Milić S; Štimac D; Mijić M; Filipec Kanižaj T; Biloglav Z; Lucijanić M; Lucijanić I; Grgurević I
Croat Med J; 2019 Dec; 60(6):494-502. PubMed ID: 31894914
[TBL] [Abstract][Full Text] [Related]
5. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and clinical course of primary biliary cholangitis in Eastern Slovakia.
Drazilova S; Babinska I; Gazda J; Halanova M; Janicko M; Kucinsky B; Safcak D; Martinkova D; Tarbajova L; Cekanova A; Jarcuska P;
Int J Public Health; 2020 Jun; 65(5):683-691. PubMed ID: 32500239
[TBL] [Abstract][Full Text] [Related]
7. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy.
Vespasiani-Gentilucci U; Rosina F; Pace-Palitti V; Sacco R; Pellicelli A; Chessa L; De Vincentis A; Barlattani M; Barlattani A; Feletti V; Mussetto A; Zolfino T; Russello M; Cozzolongo R; Garrucciu G; Niro G; Bacca D; Bertino G; Claar E; Ascione A; D'Adamo G; Adinolfi LE; Scifo G; Izzi A;
Scand J Gastroenterol; 2019 Oct; 54(10):1274-1282. PubMed ID: 31564176
[No Abstract] [Full Text] [Related]
8. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
[TBL] [Abstract][Full Text] [Related]
9. Transplantation trends in primary biliary cirrhosis.
Lee J; Belanger A; Doucette JT; Stanca C; Friedman S; Bach N
Clin Gastroenterol Hepatol; 2007 Nov; 5(11):1313-5. PubMed ID: 17900996
[TBL] [Abstract][Full Text] [Related]
10. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
Weinmann A; Sattler T; Unold HP; Grambihler A; Teufel A; Koch S; Schuchmann M; Biesterfeld S; Wörns MA; Galle PR; Schulze-Bergkamen H
J Clin Gastroenterol; 2015; 49(5):438-47. PubMed ID: 25014239
[TBL] [Abstract][Full Text] [Related]
11. Epidemiological trends and outcomes of primary biliary cholangitis in South Korea between 2009 and 2019.
Kim KA; Choi HY; Ki M; Jang ES; Jeong SH
J Gastroenterol; 2023 Jul; 58(7):682-692. PubMed ID: 37195516
[TBL] [Abstract][Full Text] [Related]
12. Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA.
Li J; Lu M; Zhou Y; Bowlus CL; Lindor K; Rodriguez-Watson C; Romanelli RJ; Haller IV; Anderson H; VanWormer JJ; Boscarino JA; Schmidt MA; Daida YG; Sahota A; Vincent J; Wu KH; Trudeau S; Rupp LB; Melkonian C; Gordon SC;
Dig Dis Sci; 2022 Aug; 67(8):4170-4180. PubMed ID: 34499271
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.
Serfaty L; De Leusse A; Rosmorduc O; Desaint B; Flejou JF; Chazouilleres O; Poupon RE; Poupon R
Hepatology; 2003 Jul; 38(1):203-9. PubMed ID: 12830003
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study.
Chang JI; Kim JH; Sinn DH; Cho JY; Kim KM; Oh JH; Park Y; Sohn W; Goh MJ; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Gut Liver; 2023 Jul; 17(4):620-628. PubMed ID: 36999383
[TBL] [Abstract][Full Text] [Related]
15. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive prediction of insufficient biochemical response after ursodeoxycholic acid treatment in patients with primary biliary cholangitis based on pretreatment nonenhanced MRI.
Zhang Y; Fan X; Song B; Liu Y; Chen Y; Zheng T; Guo Y; Duan T; Huang Z; Yang L
Eur Radiol; 2024 Feb; 34(2):1268-1279. PubMed ID: 37581659
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population.
Cançado GGL; Braga MH; Ferraz MLG; Villela-Nogueira CA; Terrabuio DRB; Cançado ELR; Nardelli MJ; Faria LC; Gomes NMF; de Oliveira EMG; Rotman V; de Oliveira MB; da Cunha SMCF; Mazo DFC; Mendes LSC; Ivantes CAP; Codes L; de Almeida E Borges VF; Pace FHL; Pessoa MG; Signorelli IV; Coral GP; Bittencourt PL; Levy C; Couto CA;
Ann Hepatol; 2022; 27(1):100546. PubMed ID: 34600142
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis.
Ozaslan E; Efe C; Heurgué-Berlot A; Kav T; Masi C; Purnak T; Muratori L; Ustündag Y; Bresson-Hadni S; Thiéfin G; Schiano TD; Wahlin S; Muratori P
Clin Gastroenterol Hepatol; 2014 May; 12(5):863-9. PubMed ID: 24076417
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular Carcinoma in Primary Biliary Cholangitis.
Sy AM; Ferreira RD; John BV
Clin Liver Dis; 2022 Nov; 26(4):691-704. PubMed ID: 36270724
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]